ABCG5 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 24 Jun 2026
  • Comments

Subtitle: Market Intelligence for Sitosterolemia & Cardiovascular Therapeutics, with High-Purity Reagents for Preclinical Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for ABCG5 drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen ABCG5 Recombinant Protein (WT & Sitosterolemia Mutant Panel)
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed.		 View ABCG5 Products
Gene Delivery ABCG5 Promise-ORF / Lentivirus
Full-length ORF for stable cell lines. Native glycosylation pattern preserved.		 View ABCG5 Products
Complex Validation ABCG8 Lentivirus (Obligate Heterodimer Partner)
Essential for ABCG5/G8 co-expression cell line generation.		 View ABCG8 Products
Benchmark Ab Anti-ABCG5 Sequence-Verified Reference Antibody
Recombinant positive control for expression validation.		 View ABCG5 Products
Validator ABCG5 siRNA Set (three unique target sites)
For knockdown verification of transport activity and specificity checks.		 View ABCG5 Products
Pathway Comparator NPC1L1 Lentivirus & Protein
Cholesterol absorption pathway target (Ezetimibe target). For selectivity screening vs. ABCG5-mediated efflux.		 View NPC1L1 Products
Associated Transporter ABCA1 Recombinant Protein
Cholesterol efflux pathway. For cross-talk studies and combination therapy rationale.		 View ABCA1 Products
Synergistic Target PCSK9
Established CVD target; combination therapy rationale for severe hypercholesterolemia.		 View PCSK9 Products

Critical Assay Challenges & the TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Multi-pass transmembrane conformation / Native folding Lentivirus Premade Particles for stable cell line generation; cell-based assays preserve native topology.
Obligate ABCG5/G8 heterodimerization required for surface trafficking Matched Lentivirus pair (ABCG5 + ABCG8 ORF) for co-expression cell line construction; also suitable for FRET/BRET dimerization assays.
Functional sterol efflux assay controls WT vs Documented Sitosterolemia Mutant Protein Panel (Sequence Verified), including Gly574Arg, Arg389Gln, etc.
Cross-species translation (Human/Mouse/Rat/Cyno) Ortholog lentivirus particles available (Human/Mouse/Rat); sequence verified for pharmacology bridging.
Tissue-specific expression (Liver/Intestine) Cell line construction kits with tissue-specific promoters for canalicular membrane localization studies.
False positives / Off-target binding in complex membrane backgrounds Validated siRNA included for specificity baseline checks; selectivity screening vs NPC1L1 and ABCA1 panels.

Live ABCG5 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The metabolic drug discovery landscape is increasingly targeting reverse cholesterol transport and sterol excretion mechanisms beyond traditional LDL-C reduction. Human genetics have firmly validated ABCG5: biallelic loss-of-function mutations cause sitosterolemia, a rare disease characterized by hyperabsorption of plant sterols and premature atherosclerosis. This provides a compelling causal biology rationale for ABCG5-directed therapies.

Current R&D efforts remain predominantly preclinical, driven by academic consortia, rare disease foundations, and selected biotech/pharma players. The dominant modalities under exploration are:

  • Gene Therapy (AAV, mRNA, CRISPR): Hepatotropic delivery of wild-type ABCG5/G8 for sitosterolemia, plus gene editing approaches (e.g., by Ultragenyx, Beam Therapeutics).
  • Small Molecule Allosteric Activators: Designed to increase biliary sterol efflux for atherosclerosis, NASH, and dyslipidemia (focus by Novartis, Regeneron, and discovery-stage biotechs).
  • Antisense Oligonucleotides (ASO): Modulating ABCG5 mRNA levels for sitosterolemia (e.g., Ionis Pharmaceuticals).
  • Allosteric Modulating Antibodies/Nanobodies: Preclinical academic efforts targeting dyslipidemia.
  • Pharmacological Chaperones: Rescuing misfolded mutant transporters to restore efflux function.

As first proof-of-concept data mature, the field is expected to shift toward combination strategies that pair ABCG5 modulation with established lipid-lowering pathways (PCSK9, NPC1L1). The obligate heterodimer with ABCG8 makes drug development uniquely challenging – compounds must preserve or enhance the dimer interface.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Gene Therapy (AAV, mRNA, CRISPR) Ultragenyx, Beam Therapeutics, Academic Consortia Sitosterolemia, Familial Hypercholesterolemia Mutant vs WT functional rescue; need sequence-verified ABCG5/G8 lentivirus for co-expression.
Small Molecule Allosteric Activator Novartis, Regeneron, Discovery-Stage Biotech Atherosclerosis, NASH, Dyslipidemia Sterol efflux assay with full-length ABCG5/G8 stable cell lines; need ATPase activity reagents.
Allosteric Modulating Antibody/Nanobody Preclinical Academic Labs Dyslipidemia Selectivity vs off-target transporter panel; need ortholog (human/mouse/cyno) proteins.
Antisense Oligonucleotides (ASO) Ionis Pharmaceuticals Sitosterolemia Knockdown efficiency validation; need high-specificity siRNA controls.
Small Molecule Inhibitor (High Risk) Eli Lilly Phytosterolemia, Cholesterol Gallstone Disease Sterol binding selectivity; need ABCG5/G8 selective cell lines and counter-screens.

Genetic and Structural Foundation

ABCG5 (UniProt Q9H222) is a member of the ATP-binding cassette (ABC) transporter superfamily, subfamily G. It contains two functional domains: an ABC transporter domain and an ABC transmembrane type-2 domain. Key mutations validated in sitosterolemia include:

  • rs6756629 (Gly574Arg): pathogenic, loss-of-function.
  • rs2104866076 (uncertain significance, associated with STSL2).
  • rs758551848 (decreased maturation of glycan chains, STSL2).

These mutations underscore the importance of using verified mutant clones for functional rescue and drug screening. TarMart provides sequence-verified ORF clones for these and other documented variants.